These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33827590)

  • 1. Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
    Tang R; Liu X; Wang W; Hua J; Xu J; Liang C; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Cancer Cell Int; 2021 Apr; 21(1):196. PubMed ID: 33827590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
    Liu J; Xu W; Li S; Sun R; Cheng W
    Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
    [No Abstract]   [Full Text] [Related]  

  • 3. The coagulation-related genes for prognosis and tumor microenvironment in pancreatic ductal adenocarcinoma.
    Wang D; Cui SP; Chen Q; Ren ZY; Lyu SC; Zhao X; Lang R
    BMC Cancer; 2023 Jun; 23(1):601. PubMed ID: 37386391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of m
    Yao Y; Luo L; Xiang G; Xiong J; Ke N; Tan C; Chen Y; Liu X
    Gland Surg; 2022 Jan; 11(1):147-165. PubMed ID: 35242677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
    Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
    Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression and immune infiltration in melanoma patients with different mutation burden.
    Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
    BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions.
    Lawlor RT; Mattiolo P; Mafficini A; Hong SM; Piredda ML; Taormina SV; Malleo G; Marchegiani G; Pea A; Salvia R; Kryklyva V; Shin JI; Brosens LA; Milella M; Scarpa A; Luchini C
    Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer.
    J Gunderson A; Rajamanickam V; Bui C; Bernard B; Pucilowska J; Ballesteros-Merino C; Schmidt M; McCarty K; Philips M; Piening B; Dubay C; Medler T; Newell P; Hansen P; Tran E; Tang E; Bifulco C; Crittenden M; Gough M; Young KH
    Oncoimmunology; 2021 Mar; 10(1):1900635. PubMed ID: 33796412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rare case of sporadic mismatch repair deficient pancreatic ductal adenocarcinoma that responded to ipilimumab and nivolumab combination treatment: case report.
    Han MY; Borazanci E
    J Gastrointest Oncol; 2023 Feb; 14(1):458-462. PubMed ID: 36915432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated analysis of senescence-associated genes in pancreatic ductal adenocarcinoma.
    Zhu ZG; Chen L; Miao DL; Jin Y; Wu Q
    Front Genet; 2022; 13():941389. PubMed ID: 36046234
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment.
    Pu N; Chen Q; Gao S; Liu G; Zhu Y; Yin L; Hu H; Wei L; Wu Y; Maeda S; Lou W; Yu J; Wu W
    Ann Transl Med; 2019 Nov; 7(22):645. PubMed ID: 31930046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity.
    Karamitopoulou E; Andreou A; Wenning AS; Gloor B; Perren A
    Eur J Cancer; 2022 Jul; 169():64-73. PubMed ID: 35512587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation of MUC16 Is Associated With Tumor Mutational Burden and Lymph Node Metastasis in Patients With Gastric Cancer.
    Zhang F; Li X; Chen H; Guo J; Xiong Z; Yin S; Jin L; Chen X; Luo D; Tang H; Mao C; Lian L
    Front Med (Lausanne); 2022; 9():836892. PubMed ID: 35211490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations between tumor mutation burden and immune infiltrates and their prognostic value in pancreatic cancer by bioinformatic analysis.
    Cai Y; Wang X; Wang N; Wu J; Ma L; Xie X; Zhang H; Dang C; Kang H; Zhang S; Zhou Z
    Life Sci; 2021 Jul; 277():119505. PubMed ID: 33872662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
    Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H
    BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Model for Lower-Grade Glioma.
    Yin W; Jiang X; Tan J; Xin Z; Zhou Q; Zhan C; Fu X; Wu Z; Guo Y; Jiang Z; Ren C; Tang G
    Front Oncol; 2020; 10():1409. PubMed ID: 32974146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical M2 macrophages-related genes to aid therapy in pancreatic ductal adenocarcinoma.
    Xu Q; Chen S; Hu Y; Huang W
    Cancer Cell Int; 2021 Oct; 21(1):582. PubMed ID: 34717651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a metastasis-related Gene Signature for predicting the Overall Survival in patients with Pancreatic Ductal Adenocarcinoma.
    Wu M; Li X; Liu R; Yuan H; Liu W; Liu Z
    J Cancer; 2020; 11(21):6299-6318. PubMed ID: 33033514
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification and validation of a tumor mutation burden-related signature combined with immune microenvironment infiltration in adrenocortical carcinoma.
    Luo Y; Chen Q; Lin J
    Math Biosci Eng; 2022 May; 19(7):7055-7075. PubMed ID: 35730296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer.
    Wu Z; Wang M; Liu Q; Liu Y; Zhu K; Chen L; Guo H; Li Y; Shi B
    Int J Med Sci; 2020; 17(1):89-96. PubMed ID: 31929742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.